| Drug Name: | Bevacizumab (216974-75-3) |
|---|---|
| PubChem ID: | 124036100 |
| SMILES: | C1CC=C(C=C1)C2=CC(=C3C=CC4=C5C3=C2C=CC5=C6C=C4N(C7=CC=CC(=C7)C(C8=CCCC(=C8)N6C9=C(CCC=C9)C1=CC=CC=C1)CCC1=CC=CC=C1)C1CC=CC=C1C1=CC=CC=C1)C1CC=CC=C1 |
| InchiKey: | MZOYWLJTGOWQCD-UHFFFAOYSA-N |
| Therapeutic Category: | Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antineoplastic Agents, Growth Inhibitors, Growth Substances |
| Molecular Weight (dalton) | : | 967.313 |
| LogP | : | 19.3691 |
| Ring Count | : | 8 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 6.48 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category